Additional Relevant Details
“This is the first Phase 3 clinical trial to be conducted with a non-invasive, sustained release drug candidate for the treatment of glaucoma and represents an important advancement in the field of ophthalmology,” stated Robert Noecker, MD, MBA, Ophthalmic Consultants of Connecticut, and Assistant Clinical Professor, Yale University School of Medicine. “While currently approved topical therapies are effective when dosed ideally, studies show that more than 50% of patients are not compliant with their therapy within the first six months of treatment. This is a very significant issue in the treatment of glaucoma. Sustained release drug candidates such as OTX-TP address this issue directly, by allowing patients who are either unable to acquire, do not remember to, or who incorrectly administer eye drop regimens, to have a convenient way to manage their disease. The preservative-free and sustained nature of OTX-TP has the potential to improve the side effect profile as well.”